



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

**NASDAQ: CELG**

Last Trade:	102.91
Trade Time:	4:15 PM ET Jan 22, 2018
Change:	0.26 (0.253%)
Day Range	99.99 - 103.50
52-Week Range	94.55 - 147.17
Volume	12,934,277

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Jan 22, 2018 [Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy](#)
- Jan 19, 2018 [Investigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen for Patients with Locally Advanced Pancreatic Cancer](#)
- Jan 8, 2018 [Celgene Corporation Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance](#)
- Jan 7, 2018 [Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies](#)
- Jan 3, 2018 [Celgene Corporation to Announce Fourth Quarter and Full-Year 2017 Results on January 25, 2018](#)

**Upcoming Events** [\[ View all \]](#)

- Jan 25, 2018 9:00 AM ET [Celgene Corporation Q4 2017 Earnings Conference Call](#)

**Events** [\[ View all \]](#)

**Financials** [\[ View all \]](#)

- Feb 10, 2017 [Annual Report \(10-K\)](#)
- Apr 27, 2017 [Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017 [Quarterly Report \(10-Q\)](#)
- Jul 27, 2017 [Quarterly Report \(10-Q\)](#)
- Apr 27, 2017 [Quarterly Report \(10-Q\)](#)